2 weeks Ago By Defense World Staff
Ardelyx, Inc. ( NASDAQ:ARDX – Get Free Report ) insider David P. Rosenbaum sold 49,564 shares of Ardelyx stock in a transaction on Friday, September 27th.
The stock was sold at an average price of $6.92, for a total transaction of $342,982.88.
Following the completion of the transaction, the insider now directly owns 301,946 shares of the company’s stock, valued at approximately $2,089,466.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website .
Ardelyx Stock Performance Ardelyx stock traded down $0.04 during mid-day trading on Tuesday, reaching $6.85.
4,155,599 shares of the stock traded hands, compared to its average volume of 5,061,170. The stock has a market capitalization of $1.59 billion, a PE ratio of -24.
61 and a beta of 0.90. The company has a debt-to-equity ratio of 0.
68, a current ratio of 4.21 and a quick ratio of 3.99.
The business’s 50-day moving average is $5.95 and its 200-day moving average is $6.54.
Ardelyx, Inc. has a 12-month low of $3.16 and a 12-month high of $10.
13. Ardelyx ( NASDAQ:ARDX – Get Free Report ) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.
07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04.
Ardelyx had a negative net margin of 31.02% and a negative return on equity of 39.73%.
The business had revenue of $73.20 million for the quarter, compared to analysts’ expectations of $55.03 million.
During the same quarter last year, the company posted ($0.08) EPS. The company’s revenue was up 228.
3% compared to the same quarter last year. As a group, sell-side analysts predict that Ardelyx, Inc. will post -0.
26 EPS for the current fiscal year. Institutional Trading of Ardelyx Analyst Ratings Changes Several research firms have commented on ARDX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Ardelyx in a report on Thursday, June 20th.
Citigroup upped their price objective on Ardelyx from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, August 2nd.
Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Ardelyx in a research report on Friday, August 2nd. Piper Sandler lowered Ardelyx from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $15.
00 to $7.00 in a report on Tuesday, July 2nd. Finally, StockNews.
com upgraded Ardelyx from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Ardelyx has a consensus rating of “Moderate Buy” and an average price target of $11.
67. Read Our Latest Stock Analysis on Ardelyx About Ardelyx ( Get Free Report ) Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
Further Reading Five stocks we like better than Ardelyx 3 Warren Buffett Stocks to Buy Now Why Lennar Stock Could Be the Best Play in the Housing Market Overbought Stocks Explained: Should You Trade Them? 2 Energy Stocks Fueling the AI Datacenter Boom High Flyers: 3 Natural Gas Stocks for March 2022 Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech? Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter ..
